Improving heart blood flow in women with HIV and diabetes or kidney problems
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new approach to improve blood flow in the hearts of women with HIV who also have diabetes or kidney problems. It might help prevent heart disease in this population.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman (assigned female at birth).
- You must be between 45 and 75 years old.
- You must be living with HIV and have been on stable HIV medication for at least 6 months.
- You must have diabetes, or evidence of kidney disease (based on lab tests).
- You must have reduced blood flow to the heart (detected by a special heart imaging test).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an approach to help people living with HIV reach heart- and metabolism-related health goals, such as blood pressure, cholesterol, and blood sugar. It involves clinics and community partners and may offer education, support, and care coordination to remove barriers to treatment.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.